文献速递眼底病与葡萄膜炎

地塞米松玻璃体内植入物迁移至前房的多中心研究

INTRAVITREAL DEXAMETHASONE IMPLANT MIGRATION INTO THE ANTERIOR CHAMBER: A Multicenter Study From the Pan-American Collaborative Retina Study Group.
PubMed 文献 · Retina · 2020-01-01

这项多中心回顾性观察性图表审查纳入468例接受至少一次玻璃体内地塞米松植入物注射的黄斑水肿患者,评估植入物迁移至前房的患病率与危险因素。按注射次数计算迁移患病率为1.6%,迁移与白内障手术史(P=0.043)和人工晶状体状态(P=0.005)显著相关,与玻璃体切割术呈统计显著性趋势(P=0.057)。迁移植入物经镊子伴或不伴粘弹剂挤出或用连接玻璃体切割机的20G套管取出,建议发生前房迁移时快速取出。

要点

  • 按注射次数计算,植入物迁移至前房的患病率为1.6%。
  • 危险因素包括白内障手术史、玻璃体切割术史及无晶状体眼。
  • 玻璃体切割眼迁移率为4.8%,高于未行玻璃体切割者的1.6%。

核心结论

  • 玻璃体内地塞米松植入物迁移至前房的风险为1.6%,危险因素为白内障手术史、玻璃体切割术史及无晶状体眼,发生迁移时建议快速取出,尤其存在角膜水肿时。

研究设计与样本

  • 多中心、回顾性、观察性图表审查,纳入468例接受至少一次玻璃体内地塞米松注射的黄斑水肿患者,排除随访期图表信息不完整者。

主要发现

  • 按注射次数计算,468例患者中植入物迁移至前房的患病率为1.6%。
  • 植入物迁移与白内障手术史显著相关(P=0.043),与人工晶状体状态显著相关(P=0.005)。
  • 植入物迁移与玻璃体切割术呈统计显著性趋势(P=0.057)。
  • 玻璃体切割眼迁移率为4.8%,未行玻璃体切割者为1.6%。
  • 迁移植入物经镊子伴或不伴粘弹剂挤出,或用连接玻璃体切割机的20G套管取出。

关键数值与推荐

  • 迁移患病率按注射次数计算为1.6%。
  • 白内障手术史与迁移相关,P=0.043;人工晶状体状态与迁移相关,P=0.005;玻璃体切割术与迁移呈统计显著性趋势,P=0.057。
  • 玻璃体切割眼迁移率为4.8%,未行玻璃体切割者为1.6%。

临床怎么用

  • 对既往行白内障手术、玻璃体切割术或无晶状体眼的黄斑水肿患者,注射地塞米松植入物后应警惕前房迁移。
  • 发生前房迁移时建议快速取出植入物,尤其存在角膜水肿时。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To establish the prevalence and risk factors for intravitreal dexamethasone implant migration into the anterior chamber in eyes with macular edema. METHODS: This was a multicenter, retrospective, observational chart review of data that included patients with macular edema who had been treated with at least one intravitreal dexamethasone injection. Patients with incomplete chart information during the follow-up period were excluded. RESULTS: The prevalence of implant migration in 468 patients, considering the number of injections, was 1.6%, with significant associations between implant migration and cataract surgery (P = 0.043) and intraocular lens status (P = 0.005) and a trend toward statistical significance (P = 0.057) with vitrectomy. A higher rate of implant migration into the anterior chamber was observed in vitrectomized eyes (4.8%) when compared with patients who did not undergo a vitrectomy (1.6%). The implants that migrated were removed with forceps with/without viscoelastic expression or with 20-gauge cannulas connected to the vitreous cutter machine. CONCLUSION: The risk of implant migration into the anterior chamber was 1.6%. Risk factors were a history of cataract surgery or vitrectomy and aphakia. When anterior migration occurs, rapid removal is advised, especially if corneal edema is present.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Gonçalves MB, Alves BQ, Moura R, et al. INTRAVITREAL DEXAMETHASONE IMPLANT MIGRATION INTO THE ANTERIOR CHAMBER: A Multicenter Study From the Pan-American Collaborative Retina Study Group. Retina. 2020. PMID: 30789460. doi:10.1097/IAE.0000000000002475

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。